Literature DB >> 24882859

The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets.

Mital Patel1, Stephanie W Liu2, Abrar Qureshi2, Joseph F Merola1.   

Abstract

Psoriasis is a chronic inflammatory disease that encompasses a large spectrum of clinically distinct subtypes. Although chronic plaque psoriasis is reported as the most common form of psoriatic skin disease, there is growing evidence that other variants including scalp, nail, inverse, and palmoplantar psoriasis are prevalent, undertreated, and associated with significant impairment in quality of life. Currently, the Psoriasis Area and Severity Index (PASI) is the standard to assess psoriasis severity as well as response to treatment; however, the PASI has several limitations. In response to this need and as a complementary objective measure to the PASI, we created the Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI), based on patient-surveyed, patient-reported outcomes equally weighted with physician assessment of disease activity. Herein we summarize the B-SNIPI as presented at the 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

Entities:  

Keywords:  INVERSE PSORIASIS; NAIL PSORIASIS; PALMOPLANTAR PSORIASIS; PATIENT-REPORTED MEASURES; PSORIASIS INDEX; SCALP PSORIASIS

Mesh:

Year:  2014        PMID: 24882859     DOI: 10.3899/jrheum.140177

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Combination Therapy of Tacrolimus and Chinese Herb Medicated Bath in Children with Inverse Psoriasis.

Authors:  Min-Feng Wu; Su Li; Yong-Mei Qian; Xin Li; Yu Chen; Ruo-Yi Wei; Bin Li; Fu-Lun Li
Journal:  Chin J Integr Med       Date:  2017-09-15       Impact factor: 1.978

2.  Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR).

Authors:  Maria Schneeweiss; Joseph F Merola; Elizabeth W Karlson; Daniel H Solomon
Journal:  BMC Dermatol       Date:  2017-08-16

3.  Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Authors:  B E Elewski; C S Baker; J J Crowley; Y Poulin; M M Okun; B Calimlim; Z Geng; O Reyes Servin; P A Rich
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-09-04       Impact factor: 6.166

Review 4.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.

Authors:  Joseph F Merola; Abrar Qureshi; M Elaine Husni
Journal:  Dermatol Ther       Date:  2018-03-06       Impact factor: 2.851

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.